Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Development of Monoclonal Antibodies Targeting Canine PD-L1 and PD-1 and Their Clinical Relevance in Canine Apocrine Gland Anal Sac Adenocarcinoma

L. Minoli, L. Licenziato, M. Kocikowski, M. Cino, K. Dziubek, S. Iussich, A. Fanelli, E. Morello, M. Martano, T. Hupp, B. Vojtesek, M. Parys, L. Aresu

. 2022 ; 14 (24) : . [pub] 20221214

Status neindexováno Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22031039

Canine apocrine gland anal sac adenocarcinoma (AGASACA) is an aggressive canine tumor originating from the anal sac glands. Surgical resection, with or without adjuvant chemotherapy, represents the standard of care for this tumor, but the outcome is generally poor, particularly for tumors diagnosed at an advanced stage. For this reason, novel treatment options are warranted, and a few recent reports have suggested the activation of the immune checkpoint axis in canine AGASACA. In our study, we developed canine-specific monoclonal antibodies targeting PD-1 and PD-L1. A total of 41 AGASACAs with complete clinical and follow-up information were then analyzed by immunohistochemistry for the expression of the two checkpoint molecules (PD-L1 and PD-1) and the presence of tumor-infiltrating lymphocytes (CD3 and CD20), which were evaluated within the tumor bulk (intratumor) and in the surrounding stroma (peritumor). Seventeen AGASACAs (42%) expressed PD-L1 in a range between 5% and 95%. The intratumor lymphocytes were predominantly CD3+ T-cells and were positively correlated with the number of PD-1+ intratumor lymphocytes (ρ = 0.36; p = 0.02). The peritumor lymphocytes were a mixture of CD3+ and CD20+ cells with variable PD-1 expression (range 0-50%). PD-L1 expression negatively affected survival only in the subgroup of dogs treated with surgery alone (n = 14; 576 vs. 235 days). The presence of a heterogeneous lymphocytic infiltrate and the expression of PD-1 and PD-L1 molecules support the relevance of the immune microenvironment in canine AGASACAs and the potential value of immune checkpoints as promising therapeutic targets.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22031039
003      
CZ-PrNML
005      
20230127131025.0
007      
ta
008      
230119s2022 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/cancers14246188 $2 doi
035    __
$a (PubMed)36551672
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Minoli, Lucia $u Department of Veterinary Sciences, University of Turin, Largo Braccini 2, 10095 Grugliasco, Italy $1 https://orcid.org/0000000189384319
245    10
$a Development of Monoclonal Antibodies Targeting Canine PD-L1 and PD-1 and Their Clinical Relevance in Canine Apocrine Gland Anal Sac Adenocarcinoma / $c L. Minoli, L. Licenziato, M. Kocikowski, M. Cino, K. Dziubek, S. Iussich, A. Fanelli, E. Morello, M. Martano, T. Hupp, B. Vojtesek, M. Parys, L. Aresu
520    9_
$a Canine apocrine gland anal sac adenocarcinoma (AGASACA) is an aggressive canine tumor originating from the anal sac glands. Surgical resection, with or without adjuvant chemotherapy, represents the standard of care for this tumor, but the outcome is generally poor, particularly for tumors diagnosed at an advanced stage. For this reason, novel treatment options are warranted, and a few recent reports have suggested the activation of the immune checkpoint axis in canine AGASACA. In our study, we developed canine-specific monoclonal antibodies targeting PD-1 and PD-L1. A total of 41 AGASACAs with complete clinical and follow-up information were then analyzed by immunohistochemistry for the expression of the two checkpoint molecules (PD-L1 and PD-1) and the presence of tumor-infiltrating lymphocytes (CD3 and CD20), which were evaluated within the tumor bulk (intratumor) and in the surrounding stroma (peritumor). Seventeen AGASACAs (42%) expressed PD-L1 in a range between 5% and 95%. The intratumor lymphocytes were predominantly CD3+ T-cells and were positively correlated with the number of PD-1+ intratumor lymphocytes (ρ = 0.36; p = 0.02). The peritumor lymphocytes were a mixture of CD3+ and CD20+ cells with variable PD-1 expression (range 0-50%). PD-L1 expression negatively affected survival only in the subgroup of dogs treated with surgery alone (n = 14; 576 vs. 235 days). The presence of a heterogeneous lymphocytic infiltrate and the expression of PD-1 and PD-L1 molecules support the relevance of the immune microenvironment in canine AGASACAs and the potential value of immune checkpoints as promising therapeutic targets.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Licenziato, Luca $u Department of Veterinary Sciences, University of Turin, Largo Braccini 2, 10095 Grugliasco, Italy $1 https://orcid.org/0000000176203902
700    1_
$a Kocikowski, Mikolaj $u International Centre for Cancer Vaccine Science, University of Gdansk, Kladki 24, 80822 Gdansk, Poland $1 https://orcid.org/0000000173969005
700    1_
$a Cino, Marzia $u Department of Veterinary Sciences, University of Parma, Strada del Taglio 10, 43100 Parma, Italy $1 https://orcid.org/0000000317491849
700    1_
$a Dziubek, Katarzyna $u International Centre for Cancer Vaccine Science, University of Gdansk, Kladki 24, 80822 Gdansk, Poland
700    1_
$a Iussich, Selina $u Department of Veterinary Sciences, University of Turin, Largo Braccini 2, 10095 Grugliasco, Italy $1 https://orcid.org/000000030361131X
700    1_
$a Fanelli, Antonella $u Department of Veterinary Sciences, University of Turin, Largo Braccini 2, 10095 Grugliasco, Italy $1 https://orcid.org/0000000275615486
700    1_
$a Morello, Emanuela $u Department of Veterinary Sciences, University of Turin, Largo Braccini 2, 10095 Grugliasco, Italy $1 https://orcid.org/0000000298016646
700    1_
$a Martano, Marina $u Department of Veterinary Sciences, University of Parma, Strada del Taglio 10, 43100 Parma, Italy $1 https://orcid.org/0000000221590930
700    1_
$a Hupp, Ted $u Institute of Genetics and Cancer, The University of Edinburgh, Crewe Road, Edinburgh EH4 2XU, UK $1 https://orcid.org/0000000303910352
700    1_
$a Vojtesek, Borek $u Research Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Zluty kopec 7, 65653 Brno, Czech Republic $1 https://orcid.org/0000000161943705
700    1_
$a Parys, Maciej $u Royal (Dick) School of Veterinary Studies and Roslin Institute, The University of Edinburgh, Easter Bush Campus, Midlothian EH25 9RG, UK $1 https://orcid.org/0000000344563369
700    1_
$a Aresu, Luca $u Department of Veterinary Sciences, University of Turin, Largo Braccini 2, 10095 Grugliasco, Italy $1 https://orcid.org/0000000278931740
773    0_
$w MED00173178 $t Cancers $x 2072-6694 $g Roč. 14, č. 24 (2022)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36551672 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230119 $b ABA008
991    __
$a 20230127131016 $b ABA008
999    __
$a ok $b bmc $g 1889349 $s 1182372
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2022 $b 14 $c 24 $e 20221214 $i 2072-6694 $m Cancers $n Cancers $x MED00173178
LZP    __
$a Pubmed-20230119

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace